knowledge -WSS

knowledge

author：comprehensive 2025-08-24 05:59:03 - browse：1433

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Mindstrong's demise and the future of mental health care

entertainment

explore

WSS

Sanders wants to replace patents with prizes for drug inventions

Extensive review finds private equity owners jack up cost of care

Are infertility treatments 'essential' during the Covid

Researchers use wearables data and AI to predict preterm birth risk

A new ‘biological computer' targets cancer while sparing healthy cells

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

focus

knowledge

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Dementia risk linked to living in disadvantaged areas: Study

Novavax promises a turnaround & Lilly roils the obesity market

Menendez indictment could see pharma lose a key ally

Drug repurposing or repositioning? The language matters

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Medical leaders decry Supreme Court decision on affirmative action

Mindstrong's demise and the future of mental health care

Virginia high school admissions case could be legal follow

Dementia risk linked to living in disadvantaged areas: Study

hotspot

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Researchers use wearables data and AI to predict preterm birth risk

Researchers use wearables data and AI to predict preterm birth risk

Sudafed saga points to U.S. issues with evaluating older drugs

In rare move, senator releases unverified FBI source report alleging Biden bribe

Researchers use wearables data and AI to predict preterm birth risk

focus

entertainment

explore

knowledge